A 58-year-old woman with a 5-year history of Parkinson disease on levodopa/carbidopa presents with involuntary writhing movements of the trunk and limbs that occur 2–3 hours after each dose of medication. She has no fever, recent illness, or new medications. Her levodopa dose is 500 mg three times daily. Neurological examination shows choreiform movements synchronous with peak drug levels, normal cognition, and stable resting tremor. What is the most appropriate next step in management?

Explanation

## Levodopa-Induced Dyskinesia: Recognition and Management **Key Point:** Levodopa-induced dyskinesia (LID) is a predictable motor complication that emerges after 4–6 years of levodopa therapy in ~40% of patients. **Peak-dose dyskinesia** (choreiform movements at maximum drug levels) is the most common type and is managed by dose reduction and adjunctive dopaminergic agents — NOT anticholinergics or immediate surgery. ### Classification of Levodopa-Induced Dyskinesia | Type | Timing | Mechanism | Management | |------|--------|-----------|-------------| | **Peak-dose dyskinesia** | 2–3 hrs after dose (at Cmax) | Excessive dopamine stimulation | ↓ Dose, add DA agonist, MAO-B inhibitor, COMT inhibitor | | **Diphasic dyskinesia** | Early and late phases of dose cycle | Nonlinear dopamine dynamics | Smaller, more frequent doses | | **Off-period dyskinesia** | When drug levels are low | Sensitization to dopamine | Add longer-acting agents (DA agonist, patch) | **High-Yield:** In this patient, the **choreiform movements synchronous with peak drug levels** (2–3 hours post-dose) confirm **peak-dose dyskinesia**. The standard approach is: 1. **Reduce levodopa dose** (e.g., from 500 mg to 375–400 mg per dose) 2. **Add a dopamine agonist** (pramipexole, ropinirole) or **MAO-B inhibitor** (rasagiline, selegiline) to extend dopaminergic effect and reduce levodopa requirement 3. **Consider COMT inhibitor** (entacapone, tolcapone) if further optimization needed ### Pathophysiology of LID After prolonged levodopa exposure, dopamine neurons develop **pulsatile dopamine receptor stimulation** (loss of buffering capacity) → abnormal striatal plasticity → dyskinesia. This is NOT reversible by stopping levodopa; it requires **dose optimization** and **adjunctive agents** to smooth dopaminergic delivery. **Clinical Pearl:** Dyskinesia severity correlates with cumulative levodopa dose and disease duration, not with current dose alone. Reducing dose while adding a dopamine agonist or MAO-B inhibitor maintains motor control while reducing dyskinesia risk. ### Why Each Distractor Fails - **Benztropine (anticholinergic):** Worsens dyskinesia and is contraindicated in LID. Anticholinergics may help tremor but exacerbate choreiform movements. - **Entacapone monotherapy:** COMT inhibitors prolong levodopa half-life but do NOT eliminate dyskinesia if levodopa dose is not reduced. Monotherapy is ineffective. - **Immediate DBS:** Reserved for motor fluctuations and dyskinesia refractory to medical optimization (typically after 5–10 years of failed pharmacotherapy). This patient is only 5 years into PD and has not yet tried dose reduction + adjunctive agents. **Mnemonic:** **"DAME"** for LID management: - **D**ose reduction - **A**gonist addition (DA agonist) - **M**AO-B inhibitor - **E**ntacapone (COMT inhibitor) ## Algorithm for Managing Motor Complications ```mermaid flowchart TD A["Levodopa-induced dyskinesia"]:::outcome --> B{"Type of dyskinesia?"}:::decision B -->|"Peak-dose"|C["Reduce levodopa dose"]:::action B -->|"Diphasic"|D["Smaller, frequent doses"]:::action B -->|"Off-period"|E["Add longer-acting agent"]:::action C --> F["Add DA agonist or MAO-B inhibitor"]:::action D --> F E --> F F --> G{"Controlled?"}:::decision G -->|"Yes"|H["Continue medical management"]:::outcome G -->|"No after 6 months"|I["Consider DBS evaluation"]:::action I --> J["DBS if refractory"]:::action ``` [cite:Harrison 21e Ch 427; Movement Disorders Society Guidelines on Levodopa-Induced Dyskinesia]